Monday, January 7, 2013
Large cap biotechs were the
only market cap segment to end 4Q12 in the black, finishing up 1% to post a 26%
gain on the year. Small caps brought up the rear in 4Q, but only the micro-caps
closed out 2012 in the red, down 5% on the full year.
The $5 billion-plus tier
outperformed all segments for the year (see "Results by Market Cap").